DRI Capital Acquires Rights to Nanogen Royalties | GenomeWeb

DRI Capital Acquires Rights to Nanogen Royalties

Mar 31, 2008

NEW YORK (GenomeWeb News) – DRI Capital will pay Nanogen $10 million for the rights to all future royalties under a licensing agreement between Nanogen and Applied Biosystems.

According to a joint announcement from the firms, DRI Capital will receive royalties related to Nanogen’s minor groove binder technology, which was licensed by ABI for use in certain TaqMan products. The MGB technology is used for the design of oligonucleotide probes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

A Mammoth Competition

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.

Genetic History, Diversity

Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.

To Long Life

Researchers link genetic links between education and smoking and longevity.

This Week in PNAS

In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.